D. Heal

Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse

Sharon L. Smith, Eloise J. Kuijer, Filomene G. Morrison, 2024, Neuropharmacology.

A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids

J. Gosden, Sharon L. Smith, D. Heal, 2024, Frontiers in psychiatry.

A review of late-stage CNS drug candidates for the treatment of obesity

J. Gosden, D. Heal, Sharon L. Smith, 2013, International Journal of Obesity.